Analyst Sam Slutsky of LifeSci Capital maintained a Buy rating on Palvella Therapeutics, retaining the price target of $90.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sam Slutsky has given his Buy rating due to a combination of factors that highlight the potential of Palvella Therapeutics in addressing a significant unmet medical need. The recent publication by Gallagher et al. provides crucial epidemiological data on cutaneous venous malformations (CVMs), revealing a larger patient population than previously estimated. This underscores the opportunity for Palvella’s QTORIN 3.9% rapamycin, a topical formulation designed to effectively target these malformations.
Furthermore, the challenges associated with current CVM management, such as difficulty in early detection and limited effectiveness of existing therapies, emphasize the need for innovative solutions like Palvella’s product. With the Phase 2 TOIVA trial fully enrolled and results anticipated soon, there is a promising outlook for the company’s targeted treatment approach. These factors collectively support Slutsky’s positive outlook and Buy rating for Palvella Therapeutics.
In another report released yesterday, Cantor Fitzgerald also maintained a Buy rating on the stock with a $120.00 price target.